EGFR-TK Inhibitor

Phase 2Small molecule

LLuBing

EGFR-TK Inhibitor is one of 66 small molecule programs targeting Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

First-LineActive, not recruiting

Adenoid Cystic CarcinomaRecruiting

Lung CancerPreclinical

Active, not recruiting

First-LinePhase 2

Active, not recruiting

Adenoid Cystic CarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

206 competitors in Lung Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

33 2

Opdivo

Bristol-Myers Squibb

Phase 3

20 3

Tagrisso

AstraZeneca

Phase 3

19 4

Beyfortus

BeiGene

Phase 3

10 5

Abraxane

Bristol-Myers Squibb

Phase 3

7 6

Ilaris

Novartis

Phase 3

2 7

Verzenio

Eli Lilly

Phase 3

2 8

Lynparza

AstraZeneca

Phase 3

2 9

DATROWAY

Daiichi Sankyo

Phase 3

2 10

Zepzelca

Jazz Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Active, not recruiting

First-Line

NCT06020066

Clinical

Trials by Indication[1]

EGFR1 trial

E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C

Completed·IInstituto Oncológico Dr Rosell·Phase 1/2·NCT03623750·23 enrolled

Adenoid Cystic Carcinoma1 trial

Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma

Recruiting·QQingdao Central Hospital·Phase 2·NCT04974866·20 enrolled

Growth1 trial

Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC

Unknown status·ZZaiwen Fan·Phase 3·NCT03008109·80 enrolled

EGFR Mutation1 trial

EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Unknown status·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT03002844·50 enrolled

Lung Cancer1 trial

IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer

Unknown status·LLuBing·N/A·NCT03258671·160 enrolled

2 more indications

Small Cell Lung Cancer1 trial

Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer

Unknown status·XXinqiao Hospital of Chongqing·Phase 2·NCT03461185·100 enrolled

First-line1 trial

SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI

Active, not recruiting·FFudan University·Phase 2·NCT06020066·202 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for EGFR-TK Inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EGFR-TK Inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EGFR-TK Inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — LuBing company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLuBing

EGFR-TK Inhibitor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

EGFR1 trial

Adenoid Cystic Carcinoma1 trial

Growth1 trial

EGFR Mutation1 trial

Lung Cancer1 trial

Small Cell Lung Cancer1 trial

First-line1 trial

References

Drug Info

Quick Facts

Related News